· Published by Health Canada · Official notice
This is duplicated text of a letter from Eli Lilly Canada Inc. Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
January 17, 2014
Subject: Association of EFFIENT® (prasugrel hydrochloride) with increased risk of bleeding in patients treated for certain types of heart attacks at the hospital.
Eli Lilly Canada Inc. in collaboration with Health Canada would like to inform patients and their caregivers of important safety information about EFFIENT® (prasugrel hydrochloride). EFFIENT® is an antiplatelet medication which lowers the ability of blood to clot. A doctor can start EFFIENT® at the hospital around the time of a procedure to open a blocked heart artery in patients with certain types of heart attacks.
This communication is posted on the Healthy Canadians Web site and on the Eli Lilly Canada Inc. Web site.
Managing marketed health product-related side effects depends on health care professionals and consumers reporting them. Any case of serious or unexpected side effects in patients receiving EFFIENT® should be reported to Eli Lilly Canada Inc. or Health Canada.
Eli Lilly Canada Inc.
Toronto, Ontario
1-888-545-5972
You can report any suspected side effect associated with the use of health products to Health Canada by:
For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc.public@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
Sincerely,
original signed by
Doron Sagman, MD, FRCPC
Vice President, Research & Development
Eli Lilly Canada Inc.